The Gross Law Firm Reminds Marinus Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 – MRNS

Core Viewpoint - The Gross Law Firm is notifying shareholders of Marinus Pharmaceuticals, Inc. regarding a class action lawsuit due to alleged misleading statements and omissions related to clinical trial results [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from March 17, 2021, to May 7, 2024 [2]. - Allegations include that Marinus Pharmaceuticals understated the risk of failing to meet early-stopping criteria in the RAISE trial and did not disclose the potential consequences of such failure, which could impact the Phase 3 RAISE II trial [2]. - The lawsuit claims that the defendants' statements about the company's business and prospects were materially false and misleading [2]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by the deadline of August 5, 2024, to potentially become lead plaintiffs [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. - Participation in the case incurs no cost or obligation for the shareholders [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].